Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on March 17, 2014. The report addresses a specific corporate event rather than a standard financial reporting period. The company is a biotechnology firm focused on stem cell therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material event reported is the publication of final results from a Phase I safety trial for the company's NSI-566 spinal cord stem cells. The trial focused on the treatment of amyotrophic lateral sclerosis (ALS). The results were published in the peer-reviewed journal "Annals of Neurology."
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the context of the clinical trial results. The report includes a press release (Exhibit 99.01) detailing the trial publication but does not elaborate on management commentary or contingencies within the text of the 8-K itself.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for specific clinical trial data.
- Review the article in "Annals of Neurology" (DOI: 10.1002/ana.24113) to understand the safety profile of NSI-566.
- Confirm the company's current financial status through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Monitor for subsequent regulatory filings regarding the progression of the NSI-566 program following this Phase I publication.